Your browser doesn't support javascript.
loading
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management.
Park, Dong Il; Hisamatsu, Tadakazu; Chen, Minhu; Ng, Siew Chien; Ooi, Choon Jin; Wei, Shu Chen; Banerjee, Rupa; Hilmi, Ida Normiha; Jeen, Yoon Tae; Han, Dong Soo; Kim, Hyo Jong; Ran, Zhihua; Wu, Kaichun; Qian, Jiaming; Hu, Pin-Jin; Matsuoka, Katsuyoshi; Andoh, Akira; Suzuki, Yasuo; Sugano, Kentaro; Watanabe, Mamoru; Hibi, Toshifumi; Puri, Amarender S; Yang, Suk-Kyun.
Afiliación
  • Park DI; Department of Internal Medicine, Kangbuk Samsung Hospital Sungkyunkwan University, Seoul, Korea.
  • Hisamatsu T; The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.
  • Chen M; Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Ng SC; Department of Medicine and Therapeutics, Institute of Digestive Disease, LKS Institute of Health Science, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
  • Ooi CJ; Gleneagles Medical Centre and Duke-NUS Medical School, Singapore.
  • Wei SC; Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
  • Banerjee R; Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India.
  • Hilmi IN; Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Jeen YT; Department of Internal Medicine, Korea University, Seoul, Korea.
  • Han DS; Department of Internal Medicine, Hanyang University Guri Hospital, Seoul, Gyunggi, Korea.
  • Kim HJ; Department of Internal Medicine, Kyung Hee University, Seoul, Korea.
  • Ran Z; Department of Gastroenterology, Shanghai Jiao Tong University, Shanghai, China.
  • Wu K; Department of Gastroenterology, Fourth Military Medical University, Xi'an, China.
  • Qian J; Department of Gastroenterology, Peking Union Medical College, Beijing, China.
  • Hu PJ; Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Matsuoka K; Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
  • Andoh A; Department of Gastroenterology, Shiga University, Otsu, Japan.
  • Suzuki Y; Department of Internal Medicine, Toho University, Sakura, Japan.
  • Sugano K; Department of Medicine, Jichi Medical University, Tochigi, Japan.
  • Watanabe M; Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
  • Hibi T; Center for Advanced IBD Research and Treatment, Kitasato University, Tokyo, Japan.
  • Puri AS; Department of Gastroenterology, GB Pant Institute of Postgraduate Medical Education and Research, New Delhi, India.
  • Yang SK; Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
J Gastroenterol Hepatol ; 33(1): 30-36, 2018 Jan.
Article en En | MEDLINE | ID: mdl-29024102
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from nine Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 2 of the statements comprised three parts: (3) management of latent TB in preparation for anti-TNF therapy, (4) monitoring during anti-TNF therapy, and (5) management of an active TB infection after anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tuberculosis / Enfermedades Inflamatorias del Intestino / Consenso / Adalimumab / Infliximab / Gastroenterología / Antibióticos Antituberculosos / Anticuerpos Monoclonales Tipo de estudio: Diagnostic_studies / Guideline / Risk_factors_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: J Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2018 Tipo del documento: Article Pais de publicación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tuberculosis / Enfermedades Inflamatorias del Intestino / Consenso / Adalimumab / Infliximab / Gastroenterología / Antibióticos Antituberculosos / Anticuerpos Monoclonales Tipo de estudio: Diagnostic_studies / Guideline / Risk_factors_studies Límite: Humans País/Región como asunto: Asia Idioma: En Revista: J Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2018 Tipo del documento: Article Pais de publicación: Australia